Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Harvard Business School
McKesson
Boehringer Ingelheim
Medtronic

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR LYNPARZA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


505(b)(2) Clinical Trials for Lynparza

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT04538378 ↗ Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors Recruiting National Cancer Institute (NCI) Phase 2 2021-07-07 Background: Lung cancers with EGFR mutations may develop resistance to therapies targeting this protein by evolving/being transformed into small cell or neuroendocrine cancers. There are no standard treatments for it. Researchers want to see if a new combination of drugs can help. Objective: To see if the combination of durvalumab and olaparib will cause tumors to shrink. Eligibility: Adults age 18 and older who had EGFR-mutated non-small-cell lung carcinoma (NSCLC) that was treated and now transformed to SCLC or another neuroendocrine tumor. Design: Participants will be screened under a separate protocol. They may have a tumor biopsy. Participants will have a physical exam. They will have a review of their symptoms, their medicines, and their ability to do their normal activities. They will have blood tests. They will have an electrocardiogram to evaluate their heart. Participants will have a computed tomography (CT) scan, a series of x-rays taken of parts of the body. Participants will get durvalumab on Day 1 of each 28-day cycle. It is given through a small plastic tube that is put in an arm vein. They will take olaparib by mouth twice every day. They will keep a medicine diary. Participants will take the study drugs until their disease gets worse or they have unacceptable side effects. About 30 days after they stop taking the study drugs, participants will have a follow-up visit. Then they will be contacted every 6 months for the rest of their life....
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Lynparza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01116648 ↗ Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2010-03-25 This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement (recurrent). Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may help to keep cancer from growing.
NCT02032823 ↗ Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Active, not recruiting Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet Phase 3 2014-04-22 Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
NCT02032823 ↗ Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Active, not recruiting Breast International Group Phase 3 2014-04-22 Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
NCT02032823 ↗ Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Active, not recruiting Frontier Science & Technology Research Foundation, Inc. Phase 3 2014-04-22 Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lynparza

Condition Name

Condition Name for Lynparza
Intervention Trials
Breast Cancer 16
Ovarian Cancer 10
Prostate Cancer 10
Recurrent Ovarian Carcinoma 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lynparza
Intervention Trials
Breast Neoplasms 34
Carcinoma 31
Neoplasms 29
Ovarian Neoplasms 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lynparza

Trials by Country

Trials by Country for Lynparza
Location Trials
United States 811
Canada 56
Spain 35
Japan 20
United Kingdom 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lynparza
Location Trials
California 36
Texas 35
Florida 34
Pennsylvania 29
New York 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lynparza

Clinical Trial Phase

Clinical Trial Phase for Lynparza
Clinical Trial Phase Trials
Phase 4 2
Phase 3 9
Phase 2/Phase 3 3
[disabled in preview] 88
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lynparza
Clinical Trial Phase Trials
Recruiting 66
Active, not recruiting 31
Not yet recruiting 30
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lynparza

Sponsor Name

Sponsor Name for Lynparza
Sponsor Trials
AstraZeneca 62
National Cancer Institute (NCI) 50
Merck Sharp & Dohme Corp. 12
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lynparza
Sponsor Trials
Other 159
Industry 124
NIH 50
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Harvard Business School
Boehringer Ingelheim
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.